Allspring Global Investments Holdings LLC Boosts Position in Abbott Laboratories $ABT

Allspring Global Investments Holdings LLC grew its stake in shares of Abbott Laboratories (NYSE:ABT) by 11.9% in the 1st quarter, HoldingsChannel.com reports. The fund owned 468,676 shares of the healthcare product maker’s stock after acquiring an additional 50,017 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Abbott Laboratories were worth $47,983,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. J. Stern & Co. LLP grew its position in shares of Abbott Laboratories by 12,439.6% during the 4th quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock worth $4,926,279,000 after buying an additional 39,005,451 shares in the last quarter. Norges Bank purchased a new stake in Abbott Laboratories in the fourth quarter worth about $2,938,892,000. Assenagon Asset Management S.A. grew its holdings in Abbott Laboratories by 303.0% during the 1st quarter. Assenagon Asset Management S.A. now owns 4,429,571 shares of the healthcare product maker’s stock worth $454,784,000 after acquiring an additional 3,330,368 shares in the last quarter. Ninety One UK Ltd purchased a new position in Abbott Laboratories during the 4th quarter valued at about $336,815,000. Finally, Vanguard Group Inc. raised its holdings in shares of Abbott Laboratories by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker’s stock valued at $21,995,501,000 after purchasing an additional 2,402,408 shares in the last quarter. Institutional investors own 75.18% of the company’s stock.

Insider Buying and Selling

In related news, Director Daniel J. Starks acquired 10,000 shares of the company’s stock in a transaction dated Monday, April 27th. The shares were purchased at an average cost of $92.65 per share, with a total value of $926,500.00. Following the completion of the acquisition, the director directly owned 6,751,103 shares of the company’s stock, valued at $625,489,692.95. This represents a 0.15% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Philip P. Boudreau bought 2,200 shares of Abbott Laboratories stock in a transaction that occurred on Thursday, April 23rd. The stock was purchased at an average price of $91.50 per share, with a total value of $201,300.00. Following the purchase, the chief financial officer directly owned 2,200 shares in the company, valued at $201,300. The trade was a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Corporate insiders own 0.46% of the company’s stock.

Abbott Laboratories Stock Up 1.9%

Abbott Laboratories stock opened at $100.71 on Friday. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $137.49. The business has a fifty day moving average price of $89.89 and a 200-day moving average price of $102.17. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. The stock has a market capitalization of $175.41 billion, a price-to-earnings ratio of 32.59, a PEG ratio of 1.73 and a beta of 0.61.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.65% and a net margin of 11.65%.The company had revenue of $12.51 billion for the quarter, compared to analyst estimates of $12.52 billion. During the same period in the prior year, the company posted $1.26 EPS. The firm’s quarterly revenue was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Equities research analysts forecast that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend is Wednesday, July 15th. Abbott Laboratories’s payout ratio is currently 70.59%.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on ABT shares. Robert W. Baird started coverage on shares of Abbott Laboratories in a research note on Wednesday, July 1st. They set an “outperform” rating and a $121.00 price objective on the stock. Sanford C. Bernstein reduced their price objective on shares of Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $130.00 target price on shares of Abbott Laboratories in a research report on Friday. Evercore cut their price target on Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. Finally, The Goldman Sachs Group decreased their price objective on Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a research note on Wednesday, May 27th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and an average target price of $118.61.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott beat Q2 earnings expectations and raised 2026 adjusted EPS guidance to $5.45-$5.60, signaling better profit momentum for the rest of the year. Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
• Positive Sentiment: Management pointed to stronger second-half demand across multiple businesses, including nutrition, medical devices, diagnostics, and diabetes care, which supports a faster growth profile. ABT Q2 Earnings Call Flags Stronger Second-Half Setup
• Positive Sentiment: Analysts turned more constructive after the results, with JPMorgan, Citi, Piper Sandler, Wells Fargo, TD Cowen, BTIG, and RBC all lifting targets or reaffirming bullish views. These Analysts Increase Their Forecasts On Abbott Following Better-Than-Expected Q2 Results

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.